OMER Key Stats
|Revenue (Quarterly YoY Growth)||-86.17%|
|EPS Diluted (TTM)||-1.639|
|EPS Diluted (Quarterly YoY Growth)|
|Net Income (TTM)||-45.68M|
|Gross Profit Margin (Quarterly)|
|Profit Margin (Quarterly)||-7077%|
|Dividend Yield (TTM)||0%|
|Payout Ratio (TTM) Pro||Go Pro|
- 2014 FDA Drug Approval Decision Calendar The Street Nov 27
- Data on Omeros' Omidria - Analyst Blog Zacks Nov 21
- Omeros Corp (OMER) Updates on OMS302 Phase 3 in Reducing Miosis in ILR Street Insider Nov 19
- Omeros Corp. (OMER) Posts Q3 Loss of 46c/Share Street Insider Nov 7
- Fast and Furious Health Care Stocks This Week Fool Nov 6
- Omeros (OMER) Issues Positive Update for OMS721 in AMD Street Insider Nov 5
- OMEROS CORP Files SEC form 8-K, Other Events Oct 24
- 'Mad Money' Lightning Round: I Like Groupon Oct 24
- Jim Cramer's 'Mad Money' Recap: A Topsy-Turvy Market Oct 23
- Positive Data on Omeros' OMS824 - Analyst Blog Zacks Oct 18
OMER Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Omeros is up 1.37% over the last year vs S&P 500 Total Return up 30.02%, Actelion up 72.20%, and Sarepta Therapeutics down 37.46%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Balance Sheet View Statement
Pro Ratings for OMER
Pro Strategies Featuring OMER
Did Omeros make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
Omeros Corporation is engaged in the discovery, development and commercialization of pharmaceutical products for inflammation, coagulopathies and disorders of the central nervous system.